With DxS, Qiagen Moves into Personalized Medicine

Qiagen has bought up DxS, a private UK-based provider of molecular tests including one for the mutant oncogene KRAS. Like the June 2009 deal by Labcorp. for Monogram Biosciences, it shows how IVD companies with very different business models are moving towards a common ground in personalized medicine and disease management.